![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The agreement aims to develop, manufacture, and commercialise outside China and adjacent territories, HSK31858, an oral, potent, and highly selective small molecule DPP1 inhibitor with the potential to be an anti-inflammatory agent in bronchiectasis.
Lead Product(s): HSK31858
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: HSK31858
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Chiesi Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 20, 2023